中东呼吸综合征冠状病毒（MERS-CoV）中和单抗研制技术进展

Progress in development of neutralizing monoclonal antibody （ McAb ） against MERS-CoV

中东呼吸综合征冠状病毒（Middle East respiratory syndrome coronavirus,MERS-CoV）2012年在中东地区的大暴发及其快速传播能力,已成为了全球科研工作者关注的重点,寻找有效的治疗和预防措施对MERS-CoV感染防治起着至关重要的作用.临床研究证实,病毒感染者恢复期血清中含有大量的中和抗体,并具有有效的临床治疗作用,说明中和抗体能有效、安全的作为病毒感染治疗手段.纤突（spike,S）蛋白是介导MERS-CoV感染宿主细胞的关键结构蛋白,是目前此病毒中和性单抗研究的关键位点.本文综述了MERS-CoV S蛋白结构特点、中和性单抗制备免疫原类型及不同种类中和性单抗的制备方式,并结合当前研究现状展望了MERS-CoV中和单抗研发前景.

The rapid spread and outbreak of Middle East respiratory syndrome coronavirus （ MERS-CoV） in the regions of Middle East in 2012 have been a great concern for researchers worldwide. Thus, efficient preventative and therapeutic countermeasures are urgently needed. Clinical studies have con-firmed that high titers of neutralizing antibodies （ Abs） against MERS-CoV in patients during convalescence have protective potency, which indicates that neutralizing Abs are safe and effective for the treatment of MERS-CoV infection. Spike （ S） protein is a key structural protein that mediates MERS-CoV infection and currently a critical protein for studying MERS-CoV neutralizing monoclonal antibodies. This review summari-zes recent advances in identifying neutralizing McAbs against MERS-CoV through describing the structural characteristics of MERS-CoV S protein, different kinds of MERS-CoV vaccines and methods for mAbs screening. Furthermore, we propose the prospects for future research on MERS-CoV neutralizing McAbs ac-cording to the current research progress.